HIGHOutside partySupplier
Ortho-Clinical Diagnostics
“10-K Item 1A: 'we currently purchase many products, components, and materials from sole or single sources, such as Ortho'”
IDXX · Concentration risk · 10-K extracted
IDEXX Laboratories (IDXX) concentration risks
Updated
The most significant concentration IDEXX Laboratories discloses is Ortho-Clinical Diagnostics, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: IDEXX Laboratories’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's only disclosed concentration is a supply-side dependency: many products, components, and materials are currently purchased from sole or single sources, with Ortho specifically named as one such supplier. This is a high-share exposure by disclosed size with a dependency character. The breadth of the disclosure — "many products, components, and materials" rather than a single input — indicates that sole-source procurement is not isolated to a minor raw material but extends across a meaningful portion of the supply base. For a diagnostic instrument and consumables company whose products must meet stringent regulatory and performance specifications, sole-source supply relationships carry heightened operational risk relative to less regulated industries. Component substitutions typically require regulatory re-qualification, which can be time-intensive, and supply disruptions therefore have longer-tail implications than they would for a standard manufacturer. No specific percentages of cost, revenue at risk, or the proportion of the supply base that is sole-sourced are disclosed, so the exposure is qualitative in scope but assessed at the high-share level by the disclosed-size band. The Ortho reference indicates at least one named, specific dependency within the broader sole-source footprint. There are no disclosed customer, geographic, or product concentrations. The concentration profile is supply-side only and represents the primary monitoring variable: supply chain resilience for sole-sourced components and the company's ability to qualify alternative suppliers over time. For investors, the key watch item is any disclosed disruption to sole-source suppliers and the pace of supply chain diversification efforts.
For the engine’s reasoning on IDXX’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Diagnostics & Research
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ADPT | Adaptive Biotechnologies Corpor | 2 | 0 | 0 | 2 |
| CRL | Charles River Laboratories Inte | 1 | 1 | 0 | 2 |
| BLLN | BillionToOne, Inc. | 1 | 0 | 0 | 1 |
| IDXX● | IDEXX Laboratories, Inc. | 1 | 0 | 0 | 1 |
| A | Agilent Technologies, Inc. | 0 | 1 | 0 | 1 |
| DGX | Quest Diagnostics Incorporated | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.